Close Menu

    Subscribe to Updates

    Get the latest creative news from FooBar about art, design and business.

    What's Hot

    Open Secure AI Alliance aims to open-source AI security defences

    Brock Purdy Adapts To 49ers’ Kyle Shanahan-Less Start To Training Camp

    Trump asks Supreme Court to allow mail-in voting restrictions

    Facebook X (Twitter) Instagram
    Facebook X (Twitter) Instagram Pinterest VKontakte
    Sg Latest NewsSg Latest News
    • Home
    • Politics
    • Business
    • Technology
    • Entertainment
    • Health
    • Sports
    Sg Latest NewsSg Latest News
    Home»Health»Levi & Korsinsky Notifies Nutex Health Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
    Health

    Levi & Korsinsky Notifies Nutex Health Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

    AdminBy AdminNo Comments3 Mins Read
    Facebook Twitter Pinterest LinkedIn Tumblr Email
    Share
    Facebook Twitter LinkedIn Pinterest Email


    NEW YORK, Sept. 12, 2025 /PRNewswire/ — Levi & Korsinsky, LLP notifies investors in Nutex Health Inc. (“Nutex Health Inc.” or the “Company”) (NASDAQ: NUTX) of a class action securities lawsuit.

    CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Nutex Health Inc. investors who were adversely affected by alleged securities fraud between August 8, 2024 and August 14, 2025. Follow the link below to get more information and be contacted by a member of our team:

    Nutex Health Inc. Lawsuit Submission Form

    NUTX investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.

    CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (i) HaloMD, a third-party IDR vendor, was achieving lucrative arbitration results for Nutex by engaging in a coordinated scheme to defraud insurance companies; (ii) as a result, to the extent that they were the product of fraudulent conduct, revenues attributable to the Company’s engagement with HaloMD in the IDR process were unsustainable; (iii) in addition, the Company overstated the extent to which it had remediated, and/or its ability to remediate, the material weaknesses in its internal controls over financial reporting; (iv) as a result, the Company was unable to effectively account for the treatment of certain of its stock based compensation obligations; (v) as a result, Nutex improperly calculated these stock based compensation obligations as equity rather than liabilities; (vi) the foregoing increased the risk that the Company would be unable to timely file certain financial reports with the SEC; (vii) accordingly, Nutex’s business and/or financial prospects were overstated; and (viii) as a result, defendants’ public statements were materially false and misleading at all relevant times.

    WHAT’S NEXT? If you suffered a loss in Nutex Health Inc. during the relevant time frame, you have until October 21, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

    NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.

    WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.

    CONTACT:
    Levi & Korsinsky, LLP
    Joseph E. Levi, Esq.
    Ed Korsinsky, Esq.
    33 Whitehall Street, 17th Floor
    New York, NY 10004
    [email protected]
    Tel: (212) 363-7500
    Fax: (212) 363-7171
    www.zlk.com

    SOURCE Levi & Korsinsky, LLP

    Share. Facebook Twitter Pinterest LinkedIn Tumblr Email
    Admin
    • Website

    Related Posts

    cbdMD Supports the Bipartisan Lawful Hemp Protection Act to Protect Consumers and Full-Spectrum CBD Access

    Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    NewAmsterdam Pharma et le groupe Menarini reçoivent un avis favorable du CHMP recommandant l’autorisation de mise sur le marché d’Ubeslo® (obicetrapib en monothérapie) et d’Evlarco® (association à dose fixe d’obicetrapib et d’ézétimibe)

    Confusion around cyclosporiasis outbreak as RFK Jr. tries to calm concerns

    Add A Comment
    Leave A Reply Cancel Reply

    Editors Picks

    Most Impressive Team Streaks Of The 21st Century: Where Does 2024-26 Spain Rank?

    NBC’s ‘Stumble’ is a mockumentary about a cheer team with plenty of tumbling runs and heart

    Xiaomi shares post worst week in 3½ years as accidents stoke EV safety concerns

    Judge reverses Trump administration’s cuts of billions of dollars to Harvard University

    Top Reviews
    9.1

    Review: Mi 10 Mobile with Qualcomm Snapdragon 870 Mobile Platform

    By Admin
    8.9

    Comparison of Mobile Phone Providers: 4G Connectivity & Speed

    By Admin
    8.9

    Which LED Lights for Nail Salon Safe? Comparison of Major Brands

    By Admin
    Sg Latest News
    Facebook X (Twitter) Instagram Pinterest Vimeo YouTube
    • Get In Touch
    © 2026 SglatestNews. All rights reserved.

    Type above and press Enter to search. Press Esc to cancel.